Program Committee and Faculty
Continuing Education
Program Agenda
Exhibits and Sponsorship
Special Interest Section Meetings

2020 Virtual Annual Scientific Meeting (62nd)


UPDATE: Virtual Sessions launched June 13, 2020 at 9:00 AM PT

Over the last couple weeks, AHS leadership and staff have been discussing the opportunity to take content from the Annual Scientific Meeting that would have been presented live and convert it to a Virtual Meeting. After many conversations and researching vendors, the decision has been made to present portions of the Annual Scientific Meeting via a Virtual Meeting platform. For additional information, please view our FAQ page.

Registration has closed. Thank you for your interest in the meeting!



2020 Virtual Annual Scientific Meeting (62nd)



Andrew C. Charles, MD, FAHS
Los Angeles, CA

Jessica Ailani, MD, FAHS
Medstar Georgetown University Hospital
Washington, DC

Rami Burstein, PhD
Harvard Medical School
Boston, MA

Amynah Pradhan, PhD
University of Illinois at Chicago
Chicago, IL

Ana Recober, MD, FAHS
Children’s Hospital of Philadelphia
Philadelphia, PA

Ann I. Scher, PhD, FAHS
Uniformed Services University of the Health Sciences
Bethesda, MD

Todd J. Schwedt, MD, MSCI, FAHS
Mayo Clinic Arizona
Phoenix, AZ

Elizabeth Seng, PhD
Yeshiva University/Albert Einstein College of Medicine
Bronx, NY

Christina L. Szperka, MD
Children’s Hospital of Philadelphia
Philadelphia, PA

Stewart J. Tepper, MD, FAHS
Geisel School of Medicine at Dartmouth
Lebanon, NH


2020 Virtual Annual Scientific Meeting (62nd)



At the conclusion of this meeting, attendees should be better able to:

  • Identify basic mechanisms of headache disorders and how they relate to new therapies
  • Recognize patterns of headache epidemiology and their role in disability
  • Become aware of changes in brain activity that precede or accompany migraine as identified by functional imaging techniques
  • Apply an understanding of established and newly introduced therapies to clinical practice
  • Recognize how the COVID-19 pandemic is affecting clinical practice in headache medicine


The provision of quality CME is a primary mission of the American Headache Society®. The Society’s educational objectives are to continue to improve the knowledge, skills, and professional performance of physicians, psychologists, and other health professionals in the care of patients with head, neck, and orofacial pain by:

  • Providing a forum for presentation of free scientific communication on research and clinical practice
  • Providing educational symposia
  • Improving education in medical schools and residency programs
  • Identifying and developing new educational initiatives
  • Supporting educational programs directed to people with head, neck, and orofacial pain
  • Maintaining strict adherence to ACCME guidelines
  • Developing education activities and tools that are designed and then evaluated for their role in improving the learners’ competence, performance, and the overall quality and safety of the care they give to individuals suffering from head, neck, and orofacial pain


The American Headache Society® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Headache Society® takes responsibility for the content, quality, and scientific integrity of this CME activity.

The American Headache Society® designates this Other Activity (live and recorded material) for a maximum of 16.50 AMA PRA Category 1 credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.


All contributors who can affect American Headache Society CME content (including Leadership, Program Chairs, Program Committee Members, Moderators, Faculty, Speakers, Reviewers, Teachers, Authors, Medical Writers and Staff), in their respective roles, are required to disclose all relevant financial relationships with any commercial interest that could be viewed as a real or perceived conflict of interest. Contributors will also identify relevant financial relationships of their spouse, partner or immediate family. This policy is in effect to maintain adherence with the conflict of interest guidelines set by the Accreditation Council for Continuing Medical Education (ACCME) and the American Headache Society Ethics Committee.

Prior to the program, attendees will be made aware of the presence or absence of relevant financial relationships for any contributors who may affect the development, management, presentation or evaluation of the CME activity. The presence or absence of relevant financial relationships for any contributor who affects content are listed on the AHS website, mobile app (where applicable), presented verbally and in slide form. Individuals who refuse to disclose relevant financial relationships will be disqualified from being a contributor and cannot have control of, or responsibility for, the development, management presentation or evaluation of the CME activity.

Please click here to view financial disclosure information for this activity.


The American Headache Society gratefully acknowledges the educational support of the Virtual Annual Scientific Meeting from our industry supporters:

Allergan, Inc.
Eli Lilly and Company
Teva Pharmaceuticals


2020 Virtual Annual Scientific Meeting (62nd)


Preliminary Virtual Program

Click here to download a copy of the preliminary agenda including a complete list of virtual poster presentations.

Launch date: June 13, 2020

9:00 AM PT

Opening Remarks

Peter J. Goadsby, MD, PhD, FAHS

Headache Medicine in the Era of COVID-19
Headache & COVID-19: A Short-term Challenge with Long-term Insights

Patricia Pozo Rosich, MD, PhD
Vall d’Hebron Hospital
Barcelona, Spain

COVID-19 and Headache: the New York Experience

Matthew S. Robbins, MD, FAHS
Weill Cornell Medicine
New York, New York

Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers

Christina L. Szperka, MD, MSCE, FAHS
Perelman School of Medicine at the University of Pennsylvania, Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Award Presentations
Harold G. Wolff Award Lecture

Cognitive Networks Disarrangement in Patients with Migraine Predicts Cutaneous Allodynia

Antonio Russo, MD, PhD
University of Campania “Luigi Vanvitelli”
Carinaro, Campania, Italy

Early Career Award Lecture

Alterations in Functional Connectivity during Different Phases of the Triggered Migraine Attack

Nazia Karsan, MBBS, PhD
King’s College London
London, United Kingdom

Seymour Solomon Award Lecture

Observations 2020 – ‘Teaching Headache’

R. Allan Purdy, MD, FAHS
Dalhousie University
Halifax, Nova Scotia

John R. Graham Award Lecture

Practical Approach to Eye Pain and Photophobia

Kathleen B. Digre, MD, FAHS
University of Utah
Salt Lake City, Utah

Frontiers in Headache Research Award Virtual Platform Presentations
Exploring Naturally Occurring Clinical Subgroups of Post-traumatic Headache

Tommy Chan, MD
Stanford University
Palo Alto, California

Efficacy and Tolerability of CGRP Monoclonal Antibody Medications in Patients with Chronic Migraine Undergoing Treatment with OnabotulinumtoxinA

Fred Cohen, MD
Montefiore Medical Center
Great Neck, New York

Identify Biomarkers in Migraine and Cluster Headache by Improving Experimental Design

Simona Denise Frederiksen, PhD, MS
University of Calgary, Cumming School of Medicine
Calgary, Alberta

Improving Headache Management in the Pediatric Emergency Department

Jessica Hauser, MD, PhD
University of Washington, Seattle Children’s Hospital
Seattle, Washington

Trainee Headache and Education Management (THEME) Study

Candice Todd-Aziz, MD
University of Toronto
Toronto, Ontario

Endogenous Analgesia in Patients with Chronic Migraine: A Study of Conditioned Pain Modulation

Hsiangkuo Yuan, MD, PhD
Thomas Jefferson University
Philadelphia, Pennsylvania

Frontiers in Headache Research Award Virtual Poster Presentations
Real World Efficacy, Tolerability and Safety Study of Ubrogepant, Rimegepant, and Lasmiditan

Chia-Chun Chiang, MD
Mayo Clinic Arizona
Scottsdale, Arizona

Development of a Visualization Tool for Tracking Modifiable Risk Factors for Progression from Episodic to Chronic Migraine

Ami Cuneo, MD
University of Washington
Seattle, Washington

Retrospective Review of the Use of Anti-CGRP Monoclonal Antibodies to Treat Headaches in Patients with Idiopathic Intracranial Hypertension

Lindsay Frerichs, MD
UT Southwestern
Dallas, Texas

Real-World Experience with Calcitonin Gene-related Peptide (CGRP) Antagonists in the Treatment of Migraine

Payal Patel Soni, MD
Cleveland Clinic
Cleveland, Ohio

A Real-World Comparison of Erenumab and Galcanezumab in a Tertiary Headache Center

Alise Pham, DO
Brigham and Women’s Hospital, Harvard Medical School
Boston, Massachusetts

5th Annual Migraine Moment Short Film Contest
Abstract Virtual Platform Presentations
Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-year Follow-up Survey Results
Effects of Pre-Injury Migraine Frequency on Post-Traumatic Headache Recovery in the General Adult Population: The Toronto Concussion Study
Exploring the Boundaries Between Episodic and Chronic Migraine: Results from the CaMEO Study
Identifying Barriers to Care-seeking, Diagnosis, and Preventive Medication Among Those with Migraine: Results of the OVERCOME Study
Inter and Intra-individual Differences in the Association Between Menstruation and Migraine
Migraine as a Risk Factor for Dementia: A National Register-based Follow-up Study
Mild Traumatic Brain Injury Induces Long-lasting Sensitization to Pain in Mice
Prevalence of Headache and Comorbidities among Men and Women Veterans across the Veterans Health Administration – a 10-year Cohort Study
Role of PAR-2 Receptors in Migraine Using a Novel, Translatable Injury-Free Preclinical Model
Survivors of Military Sexual Trauma face increased risk of Migraine Headaches and Worse Headache Care
The Impact of Migraine on Pregnancy Plan: Insights from the American Registry for Migraine Research (ARMR)
The Role of Cerebellar CGRP in Migraine-like Behavior
Industry Abstract Virtual Platform Presentations
Characteristics of Individuals with Migraine Who are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study
Consistency of the Efficacy of Single-use and Repeated-use of M207 (intracutaneous microneedle zolmitriptan) for the Acute Treatment of Migraine; Results for Pain Freedom, Pain Relief, and Sustained Pain Freedom and Pain Relief
DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Efficacy Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3 Trial
Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
Improved Functionality, Satisfaction, and Global Impression of Change with Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders
Multiple, Once-Daily, Oral Doses of 170 mg Atogepant for 28 Days Are Safe and Well Tolerated with No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults
Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-Drug Interaction Study with Lasmiditan
Pooled Analysis of Cardiovascular Safety with Fremanezumab Treatment in Patients With Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors
Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Rimegepant 75 mg Provides Early and Sustained Relief of Migraine with a Single Oral Dose: Results from 3 Phase 3 Clinical Trials
Sustained Efficacy and Safety of Erenumab in Patients with Episodic Migraine who Failed 2–4 Prior Preventive Treatments: 2-year Interim Results of the LIBERTY Open-label Extension Study
Virtual Abstract Poster Presentations by Category
*for a full listing of titles, please click here.
Industry-supported CME Program
Exhibit Showcase

Visit sponsors in the Exhibit Showcase to learn more about new products, treatments, etc.

Virtual Break Room/Meditation

Dawn C. Buse, PhD, FAHS, will walk attendees through relaxation instruction and techniques as we all face new professional and personal challenges during the COVID-19 pandemic.



2020 Virtual Annual Scientific Meeting (62nd)


Virtual Annual Scientific Meeting Registration Fees and Information

Registration has closed. Thank you for your interest in the meeting!

AHS Member and Non-member Registration Categories and Fees

Category Fee
AHS MEMBER Complimentary


Registration Information

Access information to the Virtual Annual Scientific Meeting website will be sent to the email address provided during registration on/or before the anticipated launch date of June 13, 2020.

 Acceptable Forms of Payment

Credit cards may be used for all registrations. AHS accepts Visa, MasterCard, and American Express. AHS reserves the right to charge the correct amount, if different from your calculated total. Charges will appear on your statement as “AHS Registration.”


2020 Virtual Annual Scientific Meeting (62nd)


Exhibit and Sponsorship Information


Exhibit Showcase

Once registered, visit sponsors in the Exhibit Showcase to learn more about new products, treatments, etc.

Please click here to view sponsorship opportunities for the Virtual Annual Scientific Meeting.


The American Headache Society gratefully acknowledges the support of the Virtual Annual Scientific Meeting from our industry supporters:


Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Amgen and Novartis logos

Amgen/Novartis – In August 2015, Amgen and Novartis entered into a global collaboration to develop and commercialize pioneering treatments in the field of Neuroscience. At the center of the Amgen and Novartis collaboration is the shared mission to fight migraine and the stereotypes and misperceptions surrounding this debilitating disease.

Lilly logo

Eli Lilly and Company – Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Lundbeck – For more than 70 years, Lundbeck has been at the forefront of brain science. We are committed to providing transformative therapies for brain diseases, and we are tirelessly dedicated to restoring brain health so every person can be their best.


Upsher-Smith logo

Upsher-Smith Laboratories, LLC – We at Upsher-Smith Laboratories, LLC are still carrying out our original founder’s commitment to help improve the health and lives of patients. We know that our customers have many options to choose from in the marketplace, but we believe they repeatedly choose us because we go above and beyond – striving for uninterrupted supply, quick delivery and in-depth account and patient knowledge.


Biohaven Pharmaceuticals logo


The American Headache Society gratefully acknowledges the educational support of the Virtual Annual Scientific Meeting from our industry supporters:

Allergan, Inc.
Eli Lilly and Company
John Graham Headache Center at Faulkner Hospital
Teva Pharmaceuticals


2020 Virtual Annual Scientific Meeting (62nd)


AHS members are invited to participate in Special Interest Section meetings that will be held virtually via Zoom. To access dial-in details, please log into your member account and access the event under “My Profile.”

Date Time (ET) Section
1-Jun 5:00 – 6:00 pm Post-traumatic Headache
4-Jun 6:15 – 7:15 pm Methodology, Design & Statistical Issues
4-Jun 7:30 – 8:30 pm Advanced Practice Providers
5-Jun 5:00 – 6:00 pm TMD, Cervical Spine & Orofacial Pain
5-Jun 6:15 – 7:15 pm Procedural Headache Medicine
5-Jun 7:30 – 8:30 pm New Investigators and Trainees
8-Jun 5:00 – 6:00 pm Complementary and Integrative Medicine
9-Jun 6:15 – 7:15 pm Clinical Informatics
11-Jun 7:30 – 8:30 pm Refractory, Inpatient, Emergency Care
16-Jun 6:15 – 7:15 pm Primary Front Line Headache Care
17-Jun 6:15 – 7:15 pm Behavioral Issues
22-Jun 6:15 – 7:15 pm Underserved Populations in Headache Medicine
23-Jun 6:15 – 7:15 pm Women’s Health
23-Jun 7:30 – 8:30 pm Pediatric-Adolescent Headache
24-Jun 6:15 – 7:15 pm Migraine and Vascular Disease
25-Jun 5:00 – 6:00 pm CSF Pressure & Volume Disorders
3-Aug 8:00 – 9:00 pm Trigeminal Autonomic Cephalalgias